Review led to treatment changes for 23% of patients.
It is customary to review culture results after an emergency department (ED) visit for urinary tract infection (UTI), and to call the patient to change the prescription if the organism is not sensitive to the prescribed antibiotic. Prescriptions may need to be modified for other reasons as well, such as erroneous prescribing.
Investigators retrospectively reviewed charts from all patients who had a positive urine culture (>100,000 colony-forming units/mL) after discharge from a single ED in Utah where pharmacists routinely review all such cases. Of 180 such patients over a 1-year period, 42 (23%) required a change in treatment. Of these, 31 had organisms resistant to the prescribed antibiotic, 9 were not prescribed antibiotics, 1 received tr…
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals